Ethical issues surrounding the implementation of long-acting injectable antiretroviral therapy in sub-Saharan Africa.

BACKGROUND: This article discusses the ethical issues surrounding the integration of long-acting injectable antiretroviral therapy (LA-ART) in the programmatic management of human immunodeficiency virus (HIV). As the medical landscape evolves, implementing LA-ART introduces many ethical issues that should be considered for the success of scale-up in diverse settings. METHODS: This article examines key issues such as bioethical concerns around the rollout of LA-ART, including regulatory requirements, a person's autonomy, informed consent, privacy and confidentiality; the societal implications of providing LA-ART, including the impact on stigma and discrimination; ethics around who receives LA-ART, financial accessibility, equitable access, inclusive decision-making and cultural sensitivity; and the ethics of providing an expensive intervention, including cost-effectiveness, supply chain sustainability and resource allocation. By critically analysing the ethical issues, we aim to guide policymakers and identify areas for further research. CONCLUSION: Our overarching aim is to ensure that the rights of people living with HIV are protected as implementors plan for the rollout of LA-ART with a focus on eastern and southern Africa. The utilization of LA-ART in resource-limited settings poses significant ethical challenges, necessitating careful consideration of autonomy, access and equity, stigma, discrimination, sustainability and treatment adherence.